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INCREASED RISK OF CERVICAL DYSPLASIA IN LONG TERM SURVIVORS
OF ALLOGENEIC STEM CELL TRANSPLANTATION – IMPLICATIONS FOR
SCREENING AND HPV VACCINATION
Savani, B.N.1,2, Shenoy, A.1, Stratton, P.3, Filie, A.4, Kozanas, E.1,
Chauvet, D.1, Donohue, T.1, Le, Q.1, Childs, R.W.1, Goodman, S.2,
Barrett, A.J.1. 1National Institutes of Health, Bethesda, MD; 2Veterans
AffairsMedical Center and Vanderbilt University Medical Center, Nash-
ville, TN; 3National Institutes of Health, Bethesda, MD; 4National In-
stitutes of Health, Bethesda, MD.
Cervical, skin and head-neck cancer are most common secondary
solid cancers in long-term survivors after allogeneic stem cell trans-
plantation (allo-SCT). Although these cancers are linked to human
papillomavirus (HPV) infection, the relationship betweenHPV and
cancers after allo-SCT is not defined. Furthermore, Pap smear
screening after SCT is not practiced routinely. We carried out
a cross-sectional study of 92 patients receiving allo-SCT for hema-
tological malignancies, enrolled at a minimumof 3 years post-trans-
plantation between 04/2005–06/2007 in an IRB-approved long-
term evaluation protocol.Ninety (98%) patients are alive after ame-
dian follow-up of 77 months (range 38–167). Evaluation of the 38
female patients (median age at transplant 33, range 9–60 years) in-
cluded annual gynecological examination. Thirty five received
a fractionated total body irradiation (TBI) (12–13.6 Gy) based mye-
loablative SCT and 3 received a non-TBI non-myeloablative SCT.
Acute graft versus host disease (GVHD) (grade II-IV) occurred in 9
(24%) patients and chronic GVHD in 34 (89%), extensive in 10
(26%). Six (16%) patients received immunosuppressive therapy
(IST) for chronic GVHD beyond 3 years from SCT. Thirty-five
(92%) adult patients had annual cervical smear examinations, 14
(40%) were abnormal. High grade dysplasia was seen in 8 (23%),
low grade lesions in 4 (11%) and 2 patients had atypical cells of un-
certain significance. Median time to an abnormal smear was 51
months (17–153) and median age of these 12 patients was 42 years
(range 19–62). Extensive chronic GVHD requiring prolonged
IST was the only factor associated with an increased risk of cervical
dysplasia (p 5 0.028). Our data shows that cervical dysplasia (often
high grade) is common after allo-SCT. These patients may be at in-
creased risk of developing invasive cervical cancer. Patients requir-
ing prolonged immunosuppression for chronic GVHD treatment
may be especially at risk for all forms of HPV-related malignancy.
Aggressive screening and preventive strategies with HPV vaccine
appear warranted.51
NATIONAL INSTITUTE OF HEALTH’S RECOMMENDATION FOR ASSESS-
ING LUNG FUNCTION AFTER ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION PREDICTS MORTALITY RISK
Walter, E.C.1,2, Orozco-Levi, M.3, Ramirez-Sarmiento, A.3,
Chien, J.W.1,2. 1University of Washington School of Medicine, Seattle,
WA; 2Fred Hutchinson Cancer Research Center, Seattle, WA; 3Hospital
del Mar, Barcelona, Spain.
Background: The NIH recently published a consensus state-
ment that recommends monitoring FEV1 and DLCO to evaluate
changes in lung function after allogeneic hematopoietic cell trans-
plantation (aHCT). Although this recommendation was based
upon previous analysis of pre-transplant pulmonary function tests
(PFT), their clinical validity and utility have not yet been examined.
We conducted an analysis to determine whether FEV1 and DLCO
are the most informative measurements for post-transplant lung
function change by assessing their relationship with mortality after
aHCT.Methods:Weperformed a retrospective review of 1929 pa-
tients who underwent aHCT from 1993–2002 and received PFTs
within 60–100 days after transplant. Post-transplant FEV1, FVC,
TLC, and DLCO were categorized as ./580, 70–80, 60–70 and
\ 60% predicted. FEV1/FVC ratio was categorized as ./5 0.7
and\ 0.7. Per NIH recommendations lung function score (LFS,
range 2–12) was calculated using FEV1 and DLCO. LFS was
then categorized from 0–3 (category O 5 LFS 2; category 1 5
LFS 3–5; category 25LFS 6–9; category 35LFS 10–12).Results:
Two year all cause mortality after aHCTwas 32%. Univariate anal-ysis showed a stepwise increase in mortality with each categorical
decrease in FEV1, FVC, TLC, and DLCO. There was no signifi-
cant relationship between FEV1/FVC ratio and mortality. Mortal-
ity increased with increasing LFS (category 1 hazard ratio [HR],
1.50; category 2 HR, 2.86; category 3 HR, 5.64; p\0.001; c-statis-
tic 0.6). The LFS appeared to have a stronger association with mor-
tality than did any individual lung function parameter. However,
the LFS was not uniformly distributed with a significantly lower
number of patients in LFS categories 2 and 3 (mean LFS score
3.3). Summary: These results suggest that decreased lung function
by day 100 following aHCT is a risk factor for mortality. An ele-
vated LFS is associated with an increased risk of mortality. The
LFS may serve as a mechanism to grade severity of decreased
lung function in future clinical trials. However, the scoring system
may need to be altered to improve discrimination as it is currently
weighted towards patients with normal to near normal lung func-
tion. Abbreviations: FEV15Forced expiratory volume in 1 sec,
FVC5Forced vital capacity, TLC5Total lung capacity,
DLCO5Diffusion capacity of carbon monoxide.
Two year mortality as a function of post-transplant lung function
parameters and lung function score categories
Lung function
parameters Died (%) HR (95% CI) p-valueFEV1 (%) (n 5 1929)
.80 388/1397 (28) Referent
70–80 112/310 (36) 1.39 (1.13–1.72) 0.002
60–70 66/144 (46) 1.96 (1.51–2.55) \0.001
\60 56/78 (72) 3.84 (2.90–5.09) \0.001FVC (%) (n 5 1929)
.80 429/1545 (28) Referent
70–80 103/236 (44) 1.81 (1.46–2.25) \0.001
60–70 55/101 (54) 2.44 (1.85–3.24) \0.001
\60 35/47 (74) 4.19 (2.97–5.92) \0.001TLC (%) (n 5 1904)
.80 475/1644 (29) Referent
70–80 86/187 (46) 1.87 (1.49–2.36) \0.001
60–70 33/56 (59) 2.64 (1.85–3.76) \0.001
\60 13/17 (76) 4.35 (2.51–7.55) \0.001DLCO (%) (n 5 1893)
.80 245/995 (25) Referent
70–80 127/408 (31) 1.28 (1.03–1.59) 0.023
60–70 142/311 (46) 2.12 (1.72–2.60) \0.001
\60 91/179 (51) 2.50 (1.96–3.18) \0.001LFS category (n 5 1893)
0 (LFS 2) 205/849 (24) Referent
1 (LFS 3–5) 291/851 (34) 1.50 (1.25–1.79) \0.001
2 (LFS 6–9) 96/178 (54) 2.86 (2.25–3.65) \0.001
3 (LFS 10–12) 13/15 (87) 5.64 (3.22–9.88) \0.001Definition of abbreviations: CI5 confidence interval; LFS5 Lung
function score. Data was not available for all lung function
parameters for all patients.LEUKEMIA52
A SINGLE DOSE OF GEMTUZUMAB-OZOGAMICIN (GO) IN CONSOLIDA-
TION PRIOR TO AUTOLOGOUS TRANSPLANT FOR YOUNGER PATIENTS
WITH NEWLY DIAGNOSED ACUTE MYELOID (AML) IS SAFE BUT HAS
NO EFFECT ON DISEASE FREE SURVIVAL: INTERIM RESULTS OF EAST-
ERN COOPERATIVE ONCOLOGY GROUP STUDY (E1900)
Fernandez, H.F.1, Sun, Z.2, Bennett, J.M.3, Paietta, E.M.4,
Litzow, M.R.5, Rowe, J.M.6, Tallman, M.S.7, Lazarus, H.M.8. 1H.
Lee Moffitt Cancer Center, Tampa, FL; 2Eastern Cooperative Oncology
Group, Boston, MA; 3James P Wilmot Cancer Center, Rochester, NY;
4Our Lady of Mercy Cancer Center, Bronx, NY; 5Mayo Clinic College
of Medicine, Rochester, MN; 6Rambam Medical Center, Haifa, Israel;
7R. H. Lurie Cancer Center, Northwestern University, Chicago, IL;
22 Oral Presentations8Comprehensive Cancer Center of Case Western Reserve University,
Cleveland, OH.
Gemtuzumab-Ozogamicin (GO), a CD33 directed monoclonal
antibody linked to calicheamicin, was developed to provide targeted
therapy for patients with AML. The addition of GO to standard in-
duction therapy has had promising results, particularly in its ability
to induce complete remission (CR). Its role in consolidation therapy
in AML is not defined and therefore, the main objective of E1900
was to compare the disease-free survival (DFS) of adult patients
with newly diagnosed AML, age 60 or less, between two consolida-
tion regimens: Group A received high-dose cytarabine, 3 gm/m2 ev-
ery 12 hours days 1, 3 and 5 for a total of 6 doses, for two cycles,
collected autologous peripheral blood stem cells (PBSC), then pro-
ceeded to autologous transplant with high-dose intravenous busul-
fan and cyclophosphamide with PBSC support. Group B received
the same regimen with the addition of a single dose of GO 6 mg/
m2 as an additional consolidation step after the two cycles of
high-dose cytarabine and prior to transplant. As of July 30, 2007,
553 patients were randomized to one of two induction regimens
on this trial. 254 patients have proceeded to the consolidation phase
randomization and 106 patients have completed transplant. GO in
consolidation was well tolerated, with three cases of hepatic veno-
occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) in
57 patients receiving the drug. There were no cases of VOD/SOS
post-transplant in either group. The two groups (119 eligible in
group A, 124 eligible in group B) were compared for DFS based
on the intention-to-treat (ITT) and those receiving transplant.
Eleven ineligible patients were excluded from the analysis. Results
of the planned interim analysis demonstrated the DFS was 20.0
vs. 19.5 months (p 5 0.94) and 22.2 vs. 24.9 (p 5 0.74) on the
ITT and transplant comparisons, respectively. Based on these out-
comes we conclude that GO is well tolerated in consolidation, but
does not improve DFS. E1900 continues accruing patients to eval-
uate the benefit of dose intensification of daunorubicin during in-
duction on overall survival.53
RAPAMYCIN PARTIALLY OVERCOMES THE IN VITRO PROTECTIVE EF-
FECT OF M2–10B4 MESENCHYMAL STROMAL CELLS (MSC) TO MURINE
mCGPR/1 ACUTE PROMYELOCYTIC LEUKEMIC (APL) CELLS AGAINST
CHEMOTHERAPY
Ramirez, P.A., Rettig,M., Holt,M., DiPersio, J.F.WashingtonUniver-
sity, St. Louis, MO.
Background: The mechanisms of AML-BM niche interactions
remain largely unknown. AML resistance may be related to altered
interactions and dysregulated intracellular survival signaling. Inter-
ruption of these interactions might overcome chemotherapy resis-
tance. To determine if MSC provide protection to APL cells in
vitro and how this protection might be overcome, we generated an
in vitro model of APL-MSC interaction and evaluated how soluble
and cell associated factors mediate this protection.Methods: APL
cells were obtained from mice in which a single copy of the human
PML-RARa was knocked into the murine cathepsin G locus
(mCGPR/1). APL cells were cultured in 12-well plates (normal or
transwell) with or without murine M2–10B4 MSC. After 24 h,
APL cells were untreated or treated with Ara-C or DNR for 2
days. FACS was used to test viability, cell cycle status, and prolifer-
ation kinetics using annexinV/PI, acridine orange andCFSE assays,
respectively. Results: we shown a survival benefit for APL cells co-
cultured with MSC in the absence and presence of chemotherapy
which was optimal when APL cells were in direct contact with
MSC. This benefit afforded by the MSC was maintained following
separation of the APL cells by a 0.4 mm transwell suggesting that the
anti-apoptotic stimulus provided by MSC was mediated, at least in
part, by a soluble factor released from the MSC (Table 1). APL
binding to stroma was not associated with alterations of cell cycle
nor decreased proliferation kinetics. Supernatant from MSC
showed elevation of VCAM1 (22-fold), SCF (29-fold), VEGF
(747-fold), MCP1 (979-fold), and MCP3 (907-fold). Since c-kit is
overexpressed in this APL cells and the mammalian target of rapa-
mycin (mTOR) is a downstream target for activated c-kit, we usedRapamycin to test the relevance of this pathway in resistance against
chemotherapy. Without MSC, Rapamycin increased the apoptosis
of APL cells from 40% (no Rapamycin) to 70% (20 nMRapamycin)
or 95% (20 nM Rapamycin 1 60 ng/mL Ara-C). With MSC, apo-
ptosis was increased from 40% (no Rapamycin) to 80% (Rapamycin
20 nM). Adding cytarabine to Rapamycin did not affect apoptosis.
Conclusion:MSC confer a survival advantage to APL cells in vitro.
m-TORpathway is involved in this advantage. Antibodies and small
molecules that interrupt direct binding of leukemic cells to the BM
niche or block signaling pathwaysmay be rationally used to sensitize
AML to chemotherapy in vivo.
Table 1.M2-10B4 stromal cells provide a survival advantage to
mCGPR/1 APL cells
% Apoptotic cells (AnnexinV1/PI-)Untreated
Ara-C
(40 ng/mL)
DNR
(40 ng/mL)No stroma 27%, SD 1.3 80.6%, SD 1.9 80%, SD 2.2
0.4 um transwell 4.3%, SD 4.1 12.2%, SD 0.2 10.1%, SD 2.8
Stroma 3.3, SD 0.9 8.2%, SD 0.9 5.3%, SD 0.3LYMPHOMA/MULTIPLE MYELOMA54
INCLUSION OF SIROLIMUS IN THE GVHD PROPHYLAXIS REGIMEN IS AS-
SOCIATED WITH IMPROVED SURVIVAL IN PATIENTS WITH LYMPHOMA
UNDERGOING ALLOGENEIC TRANSPLANTATION
Armand, P.1, Gannamaneni, S.2, Kim, H.T.3, Cutler, C.S.1, Ho, V.T.1,
Koreth, J.1, Alyea, E.P.1, LaCasce, A.S.1, Jacobsen, E.D.1, Fisher, D.C.1,
Brown, J.R.1, Canellos, G.P.1, Freedman, A.S.1, Soiffer, R.J.1,
Antin, J.H.1. 1Dana-Farber Cancer Institute, Boston, MA; 2Cambridge
Health Alliance, Boston, MA; 3Dana-Farber Cancer Institute, Boston,
MA.
Inhibition of mTOR has shown promising preliminary activity in
the treatment of lymphoma. Sirolimus, an mTOR inhibitor, is used
for GVHD prophylaxis in allogeneic stem cell transplantation
(SCT). We conducted a retrospective study to evaluate the effect
of sirolimus-containing GVHD prophylaxis regimens on the sur-
vival of patients with lymphoma undergoing SCT. We included
326 patients (age 18–67, median 47) who underwent SCT between
1997 and 2006. There were 150 patients with indolent B-NHL (in-
cluding 100 with CLL/SLL), 60 with aggressive B-NHL, 11 with
highly aggressive B-NHL, 31 with mantle cell lymphoma, 25 with
T-cell lymphoma, and 49 with Hodgkin’s lymphoma. 133 patients
had refractory disease at SCT. 148 received myeloablative condi-
tioning. 222 received peripheral blood stem cells, 87 received mar-
row grafts, and 17 received umbilical cord grafts. 154 were
transplanted frommatched related donors, 140 frommatched unre-
lated donors, and 32 from mismatched donors. 57 had a T-cell de-
pleted SCT, and 264 received a calcineurin inhibitor-based
regimen; among them, 137 patients received sirolimus and 173 re-
ceived methotrexate (93 of whom received both methotrexate and
sirolimus). Median follow-up for survivors was 39 months. 3-year
overall survival (OS) was 68% (95%CI, 59–77) for patients receiv-
ing sirolimus vs. 43% (95%CI, 36–50) for those not receiving it (p
\ 0.0001); 3-year progression-free survival (PFS) was 44%
(95%CI, 39–49) for patients receiving sirolimus vs. 27% (95%CI,
20–34) for those not receiving it (p\0.0001).We performed a com-
parable analysis for 1016 patients transplanted in the same time-
frame for diseases other than lymphoma. In this group, there was
no significant survival advantage for patients receiving sirolimus
(3 y OS, 42% vs. 36%, p 5 0.3; 3 y PFS, 36% vs. 30%, p 5 0.9).
The PFS and OS benefit of sirolimus-containing GVHD regimens
for lymphoma patients remained significant in multivariable analy-
ses adjusting for histology, age, chemosensitivity, conditioning reg-
imen intensity, graft source, donor HLA match, CMV serostatus,
year of SCT, and incidence of acute and chronic GVHD. In sub-
group analyses, the beneficial effect of sirolimus appeared most
